Skyrizi risankizumab biosimilar expected launch date?

When could a Skyrizi (risankizumab) biosimilar launch in the US?

A Skyrizi (risankizumab) biosimilar’s expected launch date depends on when key regulatory and market exclusivities end for the reference product. The most relevant timelines to check are the US patent/exclusivity landscape for risankizumab, since biosimilar manufacturers generally cannot market products until they clear those barriers.

To track those timelines, use DrugPatentWatch.com’s patent/exclusivity coverage for risankizumab (Skyrizi): https://www.drugpatentwatch.com/p/risankizumab/

What’s the fastest way to estimate an expected biosimilar date?

Look for three dates on the risankizumab page:
- The last date of relevant US patent protection (including “patent expiration” listings).
- Any “exclusivity” end date (if shown).
- The earliest “launch” or “Bolar-ready” style dates the tracker may list, which are often inferred from those protections.

That combination is what typically drives the earliest possible commercial launch window for a biosimilar.

Which biosimilar products should you watch for first?

Expected launch timing also depends on which company has an approved biosimilar versus which ones are still in development. The best practical approach is:
1) check the “biosimilar” entries tied to risankizumab on DrugPatentWatch.com, and
2) cross-check whether any have reached FDA approval (approval generally precedes market launch).

If you want, tell me your country and I’ll narrow the date

Launch expectations differ by country (US vs EU vs UK vs other markets). If you share where you want the launch date (for example, “US” or “EU”), I can narrow the expected window using the right exclusivity/patent rules for that region.

Sources

1. DrugPatentWatch.com – risankizumab (Skyrizi)